KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until February 17, 2026 to file lead plaintiff applications in a securities class action lawsuit against F5, Inc. (NasdaqGS: FFIV), if they purchased or otherwise acquired the Company's securities between October 28, 2024, and October 27, 2025, inclusive (the "Class Period†). This act. NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF†) and ...

Group 1 - The article highlights the upcoming deadline of December 23, 2025, for investors to participate as lead plaintiffs in a securities fraud class action lawsuit against James Hardie Industries plc [1] - The lawsuit pertains to investors who acquired common stock of James Hardie between May 20, 2025, and August 18, 2025, inclusive [1] - The company previously issued American Depositary Shares before converting to common stock on July 1, 2025 [1]

Core Viewpoint - Levi & Korsinsky has initiated a securities fraud class action lawsuit against Sprouts Farmers Market, Inc. due to alleged violations of federal securities laws [1][5]. Group 1: Company Actions - The investigation was launched on October 30, 2025, and a complaint was filed in the District of Arizona on December 17, 2025 [5]. - Sprouts reported a 4.3% decrease in comparable store growth for the third quarter compared to the second quarter, which was below previous projections [5]. - The company reduced its full-year expectations for comparable store growth from 7.5%-9% to 7% [5]. Group 2: Market Reaction - Following the announcement of disappointing growth figures, Sprouts' stock price fell by $22.64 per share, closing at $81.49 on October 30, 2025 [5]. - Analysts quickly adjusted their price targets in response to the significant slowdown in Sprouts' growth [5]. Group 3: Legal Proceedings - The deadline for determining the lead plaintiff in the class action suit is January 26, 2026 [5]. - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years [5].

Philadelphia, Pennsylvania--(Newsfile Corp. - December 22, 2025) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab [1][3]. Company Overview - Skye Bioscience, Inc. is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025, with a deadline for potential lead plaintiff representatives set for January 16, 2026 [1][2]. - The complaint alleges that the company overstated the efficacy of nimacimab and exaggerated its clinical success likelihood [3]. Financial Impact - Following the release of topline results from the 26-week Phase 2a CBeyond study, which indicated that nimacimab did not meet its primary weight-loss endpoint compared to placebo, Skye's share price plummeted by 60%, falling from $4.75 to $1.90 per share [4].

Group 1 - The law firm Halper Sadeh LLC is investigating the fairness of the merger between Laird Superfood, Inc. and Navitas LLC for Laird shareholders [1][2] - The investigation focuses on whether Laird and its board violated federal securities laws and fiduciary duties by not obtaining the best possible consideration for shareholders and failing to disclose all material information necessary for assessing the merger [2] - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction, operating on a contingent fee basis [3] Group 2 - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Ardent Health, Inc. (NYSE: ARDT) focused on whether Ardent Health and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Ardent Health investigation or if you are an Ardent Health investor who suffered a loss and ...

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, with a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [6]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [6]. Stock Price Movement - Following the announcement of disappointing financial results on September 25, 2025, CarMax's stock price dropped by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [7]. - An unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 outlook, led to an additional stock price drop of over 24% [7]. Legal Context - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in CarMax securities [3]. - Investors have until January 2, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the District of Maryland [3]. Market Dynamics - CarMax had previously promoted strong demand for its vehicles, which was allegedly inflated by a short-term boost from U.S. tariffs on cars, leading to a "pull forward" in demand [4][6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York, under the case caption West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al. [3]. Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs in this case, emphasizing that there are no costs to shareholders for litigation [7][8].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Allegations and Financial Performance - The lawsuit claims that Synopsys misled investors by stating that customers relied on its IP to minimize integration risk and that the company was experiencing strength in Europe and South Korea. However, it is alleged that customers required more customization for IP components, negatively impacting the economics of the Design IP business [5]. - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, a 43% year-over-year decline. The company indicated that increased customization demands from customers were affecting its business model [6]. Stock Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys' stock price fell from $604.37 per share to $387.78 per share, a decline of nearly 36%, indicating a significant market reaction to the revealed issues within the company [6].